Protein crystallization as a process step in a novel meso oscillatory flow reactor: study of lysozyme phase behavior by Castro, Filipa et al.
Protein Crystallization As a Process Step in a Novel Meso Oscillatory
Flow Reactor: Study of Lysozyme Phase Behavior
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ABSTRACT: In the present work, it is reported for the ﬁrst
time the study of the applicability of a novel meso oscillatory
ﬂow reactor (meso-OFR) for protein crystallization as a
process step. Crystallization assays carried out in the designed
device enabled to derive a two-dimensional lysozyme phase
diagram (lysozyme concentration against sodium chloride
concentration). Results evidence the formation of several types
of crystals (diﬀerent size and shape), with a strong inﬂuence of
salt concentration on crystal shape. Results also show that
lysozyme remains active at the end of the experiments.
Furthermore, it was possible to verify the reduction of the metastability zone when compared to lysozyme crystallization
conducted under quiescent conditions. Induction times were also measured by online monitoring of the turbidity of the
crystallization solution, obtained values being between 41 and 900 min. Beyond providing improved understanding of protein
phase behavior under oscillatory ﬂow mixing, the results are very promising regarding the feasibility of the designed methodology
for protein crystallization as a process step.
■ INTRODUCTION
Protein crystallization has been focused on the production of
diﬀraction-quality single crystals for protein structure determi-
nation by crystallography.1−3 Research conducted during the
last years has led to improved methodologies for the
production of high-quality protein crystals allowing obtaining
high-quality X-ray diﬀraction patterns, and leading thus to
information on structure biology.3 However, protein crystal-
lization also oﬀers many advantages as a means of protein
puriﬁcation at the industrial scale. Compared to conventional
puriﬁcation techniques, such as chromatography, crystallization
is a cost-eﬀective alternative since high-purity proteins can be
obtained from a single-step operation.2,4−8 Further, protein
crystals have a longer storage life and greater purity than the
dissolved form, which opens up the number of potential
applications for the pharmaceutical industry, from formulation
and storage of proteins to drug delivery.1,4,9
Unlike protein structure determination, where single, large,
stable, and well-diﬀracting crystals are required and usually
obtained by slow-growing processes, rapid and quantitative
crystallization is needed for large-scale protein puriﬁcation
processes. As most of the industrial processes, recovery yield, as
well as purity must be high and the crystallization time low, so
that growth kinetics should be fast (hours).2,4,10,11 Moreover,
reagents must be inexpensive, compounds should be of
pharmaceutical grade and proteins must not lose their potency
after crystals are redissolved.1,11 In contrast to structural
analysis, large single crystal shape is not as important, but
crystals with a certain size, shape, and mechanical strength are
desirable, so that they can be easily separated from their mother
liquor, namely by ﬁltration or centrifugation.1,2,10−12
Identiﬁcation of crystallization conditions of a protein is still
diﬃcult, particularly for puriﬁcation purposes where the
crystallization step has to meet speciﬁc requirements.4,11,13 It
requires knowledge about the thermodynamic properties of the
protein solution, concentration of the protein, temperature and
characteristics of the solvent (e.g., pH, ionic strength, buﬀer
concentration and identity, and any additives).3,14 The
traditional method to study protein solubility, in response to
diﬀerent operating conditions, is to construct a phase diagram,
commonly protein concentration against precipitant agent
concentration. A phase diagram is divided by the solubility
curve into two areas corresponding to undersaturated and
supersaturated state of a protein solution. The supersaturated
area comprises of the metastable, nucleation and precipitation
zones.3,10,11,13,14 In the nucleation and precipitation zones the
protein is either crystalline or precipitated, whereas in the
metastable zone the probability of nucleation occurrence is very
low but already existing crystals could grow.3 However,
complete phase diagrams for prediction of protein crystal-
lization are rarely available and crystallization conditions are
usually found by a trial-and-error approach. The few reports
published include the work of Hekmat12 and Smejkal5 on the
crystallization of lysozyme, the works of Smejkal9 and Hebel15
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both on the crystallization of therapeutic antibodies and more
recently the study conducted by Huettmann11 on the
crystallization of interferon gamma.
While protein crystallization is usually performed under
quiescent conditions, protein crystallization as a process step
requires a minimum of agitation. Otherwise crystals sink to the
bottom, grow into each other and the crystal growth is diﬀusion
limited leading to long process durations or low yields.9,16
Studies concerning the inﬂuence of the type and degree of
agitation on protein crystallization can be found in the
literature. A reduced nucleation time was observed in an
unbaﬄed stirred vessel,17 in a wave shaker18 and under
oscillatory ﬂow.16 Smejkal et al.5 observed a signiﬁcantly faster
onset of the crystallization of lysozyme and Fab-fragment of the
therapeutic antibody Canakinumab in stirred vessels when
compared to nonagitated systems. Besides, authors veriﬁed that
further increase of the agitation rate resulted in the decrease of
lysozyme crystallization onset. In contrast, a prolonged
nucleation time was veriﬁed in a rotary shaker19 and under
mechanical vibration.20 Vekilov and Rosenberger21 suggested
that lysozyme growth cessation and deceleration were due to
convection-enhanced supply of impurities to the interface.
Shear forces were also related to limit the attachment of
lysozyme growth units.22
Another key issue concerns the scalability of the process.1,11
Protein crystallization on process scale is usually performed in
stirred tank crystallizers. Commonly suggested scale-up criteria
such as minimum agitation rate to keep the crystals in
suspension or impeller tip speed are not always successful and
sometimes the scale-up criterion has to be based on
experimental data.9,23 Moreover, large stirred tanks are usually
characterized by low mixing eﬃciency that gives rise to excess
local concentrations,4 and in its turn leads to spontaneous
nucleation. Besides, shear stresses exerted by the impellers can
lead to protein denaturation and damaged crystals.4,7 Another
important concern is the fact that often limited amounts of
protein are available, making diﬃcult the implementation of
experiments on a large scale.
So far, only a few reports have been published on protein
crystallization as a process step. The most prominent example
is the industrial implementation of the crystallization process of
insulin.23 Other examples include studies on the crystallization
of lysozyme,5,12,15,24−26 ovalbumin,17 L-methionine γ-lyase,27
fungal lipases,10,28 and urate oxidase.29 Studies have also been
reported on more complex proteins like monoclonal antibod-
ies,9,11,30 more diﬃcult to crystallize due to their large size and
structural ﬂexibility.15 More recently, Neugebauer and Kinast7
reported the development of a tubular-plug ﬂow crystallizer for
the continuous lysozyme crystallization. Although the studies
published show the feasibility of protein crystallization as a
means of puriﬁcation, further work is required to establish the
latter as an alternative to the existing downstream processing
techniques. A limited number of works were performed under
well-deﬁned and scalable operating conditions.7 In addition,
some of the reports lack information about protein phase
behavior, crystallization kinetics and yield,31 and ﬂow
conditions.29 Furthermore, rather long process durations or
low yields were observed in most cases.9,16,29−31
To overcome some of the gaps observed in common
crystallizers, a novel meso oscillatory ﬂow reactor (meso-OFR)
was developed by members of the present research team.32 The
device is operated under oscillatory ﬂow mixing that has been
proved to result into signiﬁcant enhancement in processes such
as mass transfer and particle mixing,33,34 particularly relevant
for crystallization processes. Indeed, signiﬁcant enhancement in
crystal characteristics and reduction of operation time have
been reported for the crystallization of hydroxyapatite.35,36 In
addition, the reactor can be easily scaled up by the addition in
series of other identical meso-OFR unities. In this context, the
present work aims to study, for the ﬁrst time, the applicability
of the meso-OFR on protein crystallization for puriﬁcation
purposes. Lysozyme was used as a protein crystallization model.
Like any industrial process it is intended to obtain maximum
yield and puriﬁcation, and to achieve this rapidly. Control of
crystal size is as well important. Optimization with respect to all
these criteria has to be based on a fundamental understanding
of the process, that is, knowledge of the phase diagram and
kinetics. For this, diﬀerent experimental conditions were
screened by varying protein and precipitating agent concen-
tration in order to derive a suﬃciently quantitative crystal-
lization phase diagram of the protein under study. Induction
times were measured by online monitoring of the turbidity of
the crystallization solution. The obtained crystals were
characterized by optical microscopy and their activity was
measured. Additionally, crystal yield was estimated.
■ MATERIALS AND METHODS
Protein and Chemicals. Chicken egg-white lysozyme was
purchased from Sigma-Aldrich (Fluka-62971, Germany, lot no.
BCBJ2814 V) and was used without further puriﬁcation. One stock
solution of 0.2 M sodium acetate buﬀer at pH 4.7 was prepared using
sodium acetate trihydrate from Sigma-Aldrich (99,5%, Germany) and
glacial acetic acid from Merck (100%, Germany) to adjust the pH.
Sodium chloride was obtained from Panreac AppliChem (99,5%,
Germany). Several lysozyme (5−50 mg.mL−1) and sodium chloride
(2.5−6% (w/v)) solutions were prepared in the sodium acetate buﬀer
solution, pH of the sodium chloride solution being posteriorly
adjusted with a 1 M hydroxide sodium (Pronolab, Portugal) solution.
All the solutions were prepared in ultrapure water (Milli Q water,
resistivity of 18.2 MΩ.cm−1 at 25 °C) and ﬁltered through a 0.2 μm
cutoﬀ membrane (Sigma-Aldrich, Whatman, Germany). Lysozyme
concentrations were measured by UV spectroscopy (ScanSpec UV−
vis, Sarspec, Portugal) at 280 nm using a known extinction coeﬃcient
(2.5 L·g−1·cm−1).9
Experimental Installation. Lysozyme crystallization trials were
carried out in the experimental setup represented in Figure 1. It
involves the meso-OFR placed vertically, a mixing chamber and a
measuring cell connected to a spectrometer for turbidity measurement.
The device consists of a 35 cm long and 3 mm internal diameter glass
jacketed tube provided with smooth periodic constrictions (SPC) and
has an approximate volume of 4 mL (Figure 1). The crystallization
solution was oscillated using a piston moved by a stirring motor (CAT
R100C, United States of America). The oscillating device was custom-
built. The reactor is operated under oscillatory ﬂow mixing, controlled
by the oscillation frequency ( f) and amplitude (x0) that were ﬁxed at
1.83 Hz and 4 mm, respectively. The value of the amplitude
corresponds to the center-to-peak amplitude, and the measurements
were performed in the tube without constrictions. Reactants were fed
into the setup by means of a syringe pump (NE-4000, New Era,
United States of America). Reactants were tempered and temperature
inside the meso-OFR was regulated by a thermostatic bath (Huber,
Ministat 125, Germany) maintained at 20 °C.
Determination of Phase Diagram. Batch crystallization experi-
ments with diﬀerent lysozyme and sodium chloride concentrations
were carried out at pH 4.7 and 20 °C. As the conventional microbatch
methodology, the solution is undersaturated, saturated or super-
saturated at the beginning of each experiment. This allows a more
accurate description of phase states with known operating
conditions.3,14 Experiments were started by the simultaneous injection
in the experimental setup of equal volumes of both lysozyme and
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sodium chloride solutions. After 24h of incubation, samples were
investigated for crystals, precipitates or other structures by optical
microscopy (Standard 20, Zeiss, Germany). The supernatant was
ﬁltered and diluted with ultrapure water for lysozyme concentration
determination by UV absorbance (λ= 280 nm). This procedure was
carried out at least three times for each initial supersaturation
=
⎛
⎝⎜
⎞
⎠⎟S
C
i solubility
lysozyme initial
lysozyme
. Then, a phase diagram was assembled (Figure 2).
Induction Time. Induction time (tind) is known as the period
between the establishment of supersaturation and the detection of a
new phase.37,38 Increase of the crystals number in solution can be
detected by measuring the turbidity of the crystallization solution,
once the formation of a crystal suspension is expected to decrease light
transmission. tind can thus be determined by using the change in the
transmission of light. In this way, online measurement of the turbidity
of the crystallization solution was carried out with a spectrometer
(ScanSpec UV−vis, Sarspec, Portugal) at 400 nm to monitor the
crystallization process
τ = ×
d
A
2.303
(1)
where τ = turbidity, d = scattering path length (path length of the
measuring cell being 0.4 cm), and A = absorbance.
Absorbance measurements of the crystallization solution allowed to
build the turbidity proﬁle curves, using eq 1, for each experimental
condition studied. Figure 3 shows a typical turbidity proﬁle curve.
During the time that precedes the formation of stable nuclei, turbidity
is almost constant, while nucleation and growth of lysozyme crystals
resulted in an abrupt increase in the turbidity. In this way, tind was
derived by the intersect value, on the axis time, of the tangent to the
ﬁrst rapid increase in the turbidity proﬁle curve as illustrated in Figure
3.
Lysozyme Activity. Enzymatic activity of the lysozyme crystals
obtained was determined by spectrophotometry and compared to the
enzymatic activity of the initial lysozyme solution. The rate of lysis of
Micrococcus lysodeikticus was determined, one unit being equal to a
decrease in optical density (OD) of 0.001 per minute at 450 nm at pH
6.25 and 25 °C.
■ RESULTS AND DISCUSSION
Lysozyme Phase Behavior. Batch crystallization experi-
ments carried out in the meso-OFR enabled to derive lysozyme
phase behavior under oscillatory ﬂow mixing at 20 °C and pH
4.7 (Figure 4). The solubility39,40 and the metastability41 curves
were drawn based on the data available in the literature at
quiescent conditions. Clear solutions above the solubility curve
were indicative of the metastable region, once in spite of being
supersaturated these solutions were not able to produce
crystals. As expected, increasing concentrations of both
lysozyme and sodium chloride above the metastability curve
Figure 1. Schematic representation of the experimental setup for
lysozyme crystallization experiments in the meso-OFR: D, internal
tube diameter; do, internal diameter in the constrictions; L1,
convergent-divergent section length; L2, straight section length; Rc,
radius of the curvature of the sidewall of the convergent section; and
Rd, radius of the curvature of the sidewall of the divergent section.
Figure 2. Schematic representation of the procedure employed for the generation of lysozyme phase diagram in the meso-OFR at 20 °C and pH 4.7
and under agitation conditions of f = 1.83 Hz and x0 = 4 mm.
Figure 3. Typical turbidity proﬁle obtained during lysozyme
crystallization experiments (lysozyme 30 mg·mL−1, NaCl 4% (w/v),
pH 4.7, and T = 20 °C and under agitation conditions of f = 1.83 Hz
and x0 = 4 mm).
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led to crystallization and further increase to simultaneous
crystallization and precipitation. Several types of crystals were
observed, from tetragonal, orthorhombic and needle-shaped
crystals to microcrystals and precipitate, depending on both
reactants concentration but mostly on salt concentration
(Figure 5). For sodium chloride concentrations below and
equal to 3% (w/v), essentially tetragonal crystals were
observed. One can also verify that crystals with diﬀerent sizes
(about 5 to 15 μm) and aggregated crystals were obtained. For
sodium chloride concentration of 4% (w/v) and lysozyme
concentration between 15 and 25 mg.mL−1, samples were
constituted by well-deﬁned tetragonal and orthorhombic
crystals with typical size around 10 μm and needle-shaped
crystals. Images also demonstrate the generation of aggregated
microcrystals (with typical size about 3 μm) for higher
lysozyme concentration (30 mg.mL−1). For high concen-
trations of sodium chloride (≥5% (w/v)) and low concen-
tration of lysozyme (10 to 15 mg·mL−1) mainly needles with
regular size and shape were formed, while increasing lysozyme
concentration led to precipitation.
As known, crystallization of a protein involves reduction of
the solubility of the protein, namely by the addition of
precipitant agents.3 In the case of sodium chloride, the
solvation layer around protein molecules is reduced, giving
thus rise to solubility decrease. In this way, a direct relationship
was veriﬁed between salt concentration and the appearance of
lysozyme crystals. Results obtained also demonstrated a strong
inﬂuence of salt concentration on the shape of lysozyme
crystals. Under quiescent conditions, experimental conditions
studied should only lead to the formation of tetragonal
lysozyme crystals.39−41 However, for concentrations of sodium
chloride equal and superior to 4% (w/v) samples contain
needle-shaped crystals. Bhamidi et al.42 suggested that needles
were an unstable polymorph of lysozyme that slowly would
convert to the tetragonal form. However, observations done on
the collect suspensions kept during several months did not
prove this hypothesis for all the cases.
In the present work lysozyme crystals are subjected to ﬂuid
shear forces induced by oscillatory ﬂow mixing and solid−liquid
interfaces. Lysozyme crystals collide with parts of the glass walls
of the meso-OFR and with each other. In this way, crystalline
fragments could be created by attrition leading to secondary
nucleation that gives rise to excess nucleation and suppresses
growth, and in its turn lead to small size crystals.43 Indeed,
protein crystals are generally more fragile than crystals of
inorganic and small organic molecules because of their high
solvent content,44 so that they are highly likely to fracture
during collision with each other or the crystallization
equipment. Experimental results suggest the occurrence of a
strong nucleation, since most of the experimental conditions
studied led to the formation of a high number of small crystals
and crystals with diﬀerent sizes (Figure 5).
As shown in Figure 5, some aggregation could be observed.
In what concerns protein crystals aggregation, literature reports
many factors that can induce particle aggregation. Kusters et
al.45 suggested that aggregation for lysozyme crystals with a
diameter in the range of 1−100 μm is mainly induced by shear
forces according to its Kolmogorov microscale. Other studies46
demonstrated that shear alone do not cause aggregation
although prolonged exposure resulted in some minor reversible
aggregation. In the present work, besides the fact that the
lysozyme crystals have an average size in the order of 10 μm
(see Table 2), they are also subjected to shear stress, which may
explain their aggregation.
Figure 4. Lysozyme phase behavior in the meso-OFR at pH 4.7 and
20 °C under agitation conditions of f = 1.83 Hz and x0 = 4 mm.
Figure 5. Lysozyme crystals obtained in the meso-OFR at pH 4.7 and 20 °C under agitation conditions of f = 1.83 Hz and x0 = 4 mm. Lysozyme
concentrations used are mentioned in each picture.
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Lysozyme Activity. Regarding the activity of the crystals
collected, the results revealed that the protein collected is still
active, since most of the samples exhibited at least 80% of
activity when compared to the initial lysozyme solution.
It is commonly believed that denaturation is a prerequisite
for aggregation, once small perturbations in protein structure
may expose hydrophobic surfaces, causing self-interactions and
consequential aggregation.46 According to the literature,47 long
exposure time at solid−liquid interfaces48 and a moving gas−
liquid interface46,49−52 can cause damage to proteins. It has also
been reported that this phenomenon is mainly due to the
hydrophobic character of such interfaces.46 In the meso-OFR,
lysozyme crystals are subjected to ﬂuid shear forces and solid−
liquid interfaces. Furthermore, they are exposed to air−liquid
interfaces, although there have been attempts to minimize
them, once reactants were carefully injected in the system to
avoid bubbles and the reactor was almost completely full. Given
the little loss of activity, the aggregation observed may be
mainly explained by exposure to shear stress as already
suggested above.
Metastability Curve Determination. On the basis of
lysozyme phase behavior (Figure 4), it was possible to
determine the metastability curve based on the minimum
sodium chloride concentration needed for nucleation at
diﬀerent lysozyme concentrations. Given the uncertainty
associated with the experimental results and the stochastic
nature of nucleation, a potential range for the metastability
curve was represented (error bars). These results, as well as the
solubility and metastability curves reported in the literature for
microbatch experiments39,40 were linearized (see Figure 6)
according to Martins et al.40 equation
=
⎛
⎝⎜
⎞
⎠⎟C A
B
C
explysozyme
NaCl (2)
where Clysozyme is the lysozyme concentration in milligrams per
milliliter, and CNaCl is the concentration of sodium chloride in
percentage units (w/v). The values of the constants A and B
that best ﬁt the experimental results are given in Table 1.
According to Figure 6 and Table 1, metastability data can be
described by the exponential relationship proposed by Martins
et al.,40 used for the description of lysozyme solubility curve
with sodium chloride as the precipitant agent.
Reduction of the Metastability Zone. From the
experimental and literature results (Figures 4 and 6), it was
possible to illustrate the undersaturation, metastable, nucleation
and precipitation zone (Figure 7), hence giving information
about the relevant range of sodium chloride and protein
concentration for lysozyme crystallization in the meso-OFR at
20 °C and pH 4.7.
Graphical representation of the experimental metastability
curve and both theoretical solubility and metastability curves
clearly illustrates the reduction of the metastability zone when
performing lysozyme crystallization under oscillatory ﬂow
mixing (Figure 7). For instance, for a lysozyme concentration
of 15 mg·mL−1, crystals were observed at Si = 5.4 with
oscillatory ﬂow mixing, while under quiescent conditions
appearance of crystals is only expected for Si values superior
or equal to 6.3 (metastability data). Under agitation, collision
between protein molecules is increased, increasing thus
nucleation probability. As a result, metastability region is
reduced leading to the occurrence of nucleation at lower
supersaturation levels. Therefore, crystallization conditions that
normally do not produce crystals may become successful using
oscillatory ﬂow mixing. This could be particularly interesting for
proteins with a limited range of crystallization conditions, since
the probability of crystals appearance can be increased under
oscillatory ﬂow mixing.
Figure 6. Linearized metastability curve for lysozyme crystallization carried out in the meso-OFR at 20 °C and pH 4.7 and under agitation conditions
of f = 1.83 Hz and x0 = 4 mm. Solubility and metastability curves were obtained by curve ﬁtting from data reported in the literature.
39−41
Table 1. Values of A and B Constants from the Linearization
of Both Experimental Metastability and Theoretical
Solubility and Metastability Curves of Lysozyme at 20 °C
and pH 4.7
linearized curve A B r2
solubility39,40 0.354 8.45 0.973
metastability41 3.744 6.19 0.983
metastability−meso-OFR 1.887 7.52 0.970
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Induction Time. Measured induction time, tind, was plotted
as a function of the initial supersaturation, Si, for the
experimental conditions studied (Figure 8).
Nucleation is time-critical during protein crystallization
processes as it determines the onset of crystallization. Further,
nucleation controls crystal product quality aspects such as the
kind of solid state and crystal size distribution.37 In this study,
crystallization onset was evaluated through tind measurement.
According to Figure 8, typical values for tind are between 41 and
900 min depending on the initial supersaturation Si. It is also
important to refer that tetragonal crystals were essentially
obtained at low Si, that is, at large tind, while needles and
precipitates were preferentially formed at high Si, that is, at
short tind. One can also verify that for sodium chloride
concentrations of 4% and 5% (w/v), tind decreases as Si
increases, while no direct relationship between Si and tind was
evidenced for a sodium chloride concentration of 3% (w/v). It
is important to mention that the value of the induction time
depends strongly on the methodology employed to detect the
formation of new nuclei. In this study, measurement of the
induction time is based on the detection of an abrupt increase
in the turbidity of the crystallization solution, thereby a
considerable number of crystals have to be formed to detect a
signiﬁcant increase in the turbidity of the solution. For the
highest sodium chloride concentrations, experiments were
characterized by a strong nucleation giving rise to a high
number of crystals in solution, and in turn an important
increase in the turbidity of the solution. In contrast, lower
sodium chloride concentration experiments did not lead to a
noteworthy change in the turbidity of the solution, in particular
when only tetragonal crystals were observed. For those cases,
crystallization solutions kept relatively clear throughout the
experiment despite the presence of crystals in solution. This
partly explains the large variation in the induction time values
(error bars), which can also be explained by the stochastic
nature of nucleation and the low probability that nuclei form at
low supersaturations. From Figure 8, one can verify that for the
same sodium chloride concentrations (4% (w/v)) and lower Si,
Figure 7. Lysozyme phase diagram in the meso-OFR at pH 4.7 and 20 °C under agitation conditions of f = 1.83 Hz and x0 = 4 mm.
Figure 8. Induction time tind as a function of the initial supersaturation Si for diﬀerent sodium chloride concentrations: 3% (w/v), 4% (w/v), and 5%
(w/v). The error bars are standard deviations from at least three independent experiments. Smejkal et al.5 data was obtained in a stirred tank reactor
of 6 mL for diﬀerent stirrer speeds from 200 to 400 rpm with sodium chloride concentration of 4% (w/v) and lysozyme concentration of 50 mg·
mL−1.
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values of tind are shorter than the values reported in the
literature.5 Indeed, Smejkal et al.5 related crystallization onsets
from 350 to 570 min (stirrer speeds from 400 to 200 rpm,
respectively) in a 6 mL-scale stirred tank for Si = 9.7, while we
observed values of 80 and 338 min for Si of 8.9 and 7.1,
respectively. As already mentioned, the eﬃcient oscillatory ﬂow
mixing mechanism developed in the meso-OFR leads to
enhanced mass transfer, minimizing thus diﬀusion limitations
that were reported to be the main bottleneck in the lysozyme
crystallization process in nonagitated systems.5
Summary of Experimental Conditions. Table 2
summarizes the experimental crystallization conditions studied,
as well as the respective crystals characteristics.
According to Table 2, criteria for protein crystallization as a
process step were fulﬁlled,1 since well-deﬁned lysozyme crystals
with a typical size around 10 μm were formed for low reagents
concentrations. In addition, lysozyme crystals maintained their
activity at the end of the process, since for most of the
experimental conditions studied collected crystals exhibited at
least 80% of activity. Further, crystallization process was
relatively fast, since for certain operating conditions it was
possible to detect the appearance of crystals after a few minutes.
Regarding crystal yield, it was estimated using
=
−
×
C C
C
yield (%) 100lysozyme intial lysozyme final
lysozyme initial (3)
where Clysozymeinitial and Clysozymefinal are the initial and ﬁnal
lysozyme concentration estimated through UV absorbance (λ =
280 nm), respectively. In general the amount of crystals formed
is low and further optimization is required, since yields of about
70% have been reported in the literature.5 For certain
experimental conditions, it was not possible to evaluate
precisely the size of the crystals, namely, when needles and
precipitates were formed. Overlapping of the needles and small
size and amorphous nature of precipitates prevented a proper
assessment of their size.
■ CONCLUSION
The present work reports for the ﬁrst time the study of
lysozyme phase behavior in a novel meso oscillatory ﬂow
reactor (meso-OFR). For this, various experimental conditions
were screened by varying lysozyme and sodium chloride
concentration at pH 4.7 and T = 20 °C and under ﬁxed
agitations conditions ( f = 1.83 Hz and x0 = 4 mm). The results
obtained enabled the elaboration of a two-dimensional
lysozyme phase diagram (lysozyme concentration against
sodium chloride concentration). It was possible to observe
several types of crystals, from tetragonal, orthorhombic and
needle-shaped crystals, to microcrystals and precipitates.
Results further suggest a strong inﬂuence of salt concentration
on the shape of lysozyme crystals. Furthermore, lysozyme
crystals formed remain active at the end of the experiments. It
was also shown that oscillatory ﬂow mixing promotes
nucleation at low supersaturation, since results evidenced the
reduction of the metastable zone and short induction times.
This study may thus provide improved understanding of
protein phase behavior under agitation, in particular under
oscillatory ﬂow mixing. Although further optimization is still
required, especially regarding yield and control of crystals’
characteristics (size and morphology), results are very
promising regarding the applicability of the designed meso-
OFR for protein crystallization as a process step. Indeed,
oscillatory ﬂow mixing can induce nucleation in conditions
where nucleation normally (quiescent conditions) does not
occur, which can be particularly interesting from an industrial
point of view.
■ AUTHOR INFORMATION
Corresponding Author
*Tel.: +351 22 508 16 87. E-mail: ﬁlipaj@fe.up.pt.
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
This work was ﬁnancially supported by the European Regional
Development Fund (FEDER) through COMPETE 2020
Operational Programme Competitiveness and Internationaliza-
tion (POCI) (UID/EQU/00511/2013-LEPABELaboratory
for Process Engineering, Environment, Biotechnology and
EnergyEQU/00511; POCI-01-0145-FEDER-006684) and
by national funds through FCTPortuguese Foundation for
Science and Technologyunder the projects: UID/BIO/
04469/2013; IF exploratory project [IF/01087/2014]; post-
doctoral Fellowship [SFRH/BPD/96132/2013]. A. Ferreira is
an Investigator FCT (IF/01087/2014).
Table 2. Experimental Conditions for Lysozyme Crystallization As a Process Step in the meso-OFR at 20 °C and pH 4.7 and
under Agitation Conditions of f = 1.83 Hz and x0 = 4 mm
[NaCl]
(% (w/v)) [Lysozyme] (mg·mL−1) Si typical crystal size (μm) crystal shape
crystal yield
(%)
relative activity
(%) tind (min)
2.5 50 33.3 10 ± 4.6 tetragonal
3 25 3.4 9.3 ± 4.0 tetragonal 47.5 ± 11.9 >85 528 ± 239
30 4.1 9.8 ± 3.9 43.6 ± 21.5 465 ± 15
35 4.8 8.4 ± 3.4 36.2 ± 22.7 735 ± 135
40 5.5 7.6 ± 4.1 76.0 ± 12.5 552 ± 19
4 15 5.4 6.5 ± 2.9, 10−50a tetragonal, orthorhombic, and
needle
20.6 >80 772 ± 106
20 7.1 13 ± 8.8, ∼20a 40.1 ± 12.9 338 ± 60
25 8.9 10 ± 5.1, ∼30a 50.5 ± 14.6 80
30 10.7 3.4 ± 2.3 microcrystals 52.1 ± 47.5 41 ± 1
5 10 5.5 10−15 needle 36.3 ± 4.1 >85 917 ± 34
15 8.3 ∼15 8.2 ± 4.2 566
20 11.0 precipitate 13.9 ± 4.1 114 ± 6
6 10 6.7 20−50 needle
aThese values correspond to the typical value of the length of the needles, their width being in the order of 1−2 μm.
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